Table 1.
Characteristics of study participants in discovery and replication cohorts
| Characteristics | AGES-Reykjavik | ARIC† | ASPS | CHS† | FHS | Rotterdam Study I | Rotterdam Study II | 3C-Dijon | AGES II |
|---|---|---|---|---|---|---|---|---|---|
| Number with MRI and genotype data | 2762 | 820 | 765 | 2184 | 2319 | 421 | 591 | 1449 | 1773 |
| Excluded for TIA or stroke | 295 | 22 | 0* | 0* | 87 | 41 | 24 | 32 | 166 |
| Number in analyses | 2467 | 798 | 765 | 2184 | 2200 | 380 | 567 | 1417 | 1607 |
| Mean ± SD age at MRI | 76.1 ± 5.4 | 63.1 ± 4.4 | 65.1 ± 8.0 | 71.8 ± 4.9 | 63.9 ± 11.3 | 72.7 ± 7.7 | 67.2 ± 5.3 | 72.3 ± 4.1 | 76.4 ± 5.6 |
| Number of men (%) | 1007 (40.8%) | 333 (41.7%) | 331 (43.3%) | 851 (38.97%) | 1010 (45.9) | 176 (46.4) | 283 (49.9) | 554 (39.1%) | 672(41.8%) |
| Mean ± SD log(WMH+1) | 1.19 ± 0.85 | 0.83 ± 0.38 | 0.89 ± 0.88 | 0.70 ± 0.22 | 0.69 ± 0.61 | 1.98 ± 1.21 | 1.22 ± 0.87 | 1.46 ± 0.67 | 1.20 ± 0.84 |
| Mean WMH burden ± SD | 3.84 ± 4.47 | 1.47 ± 0.98 | 3.12 ± 6.75 | 2.19 ± 1.40 | 1.65 ± 3.51 | 13.09 ± 14.58 | 5.21 ± 7.36 | 5.50 ± 4.88 | 3.79 ± 4.25 |
| Median (IQR) WMH burden | 2.0 (0.6; 5.8) | 1.0 (1.0; 2.0) | 0.9 (0.2; 3.1) | 2 (1.0; 3.0) | 0.6 (0.3; 1.4) | 7.8 (0.7; 15.0) | 3.1 (1.3; 5.0) | 4.0 (2.8–6.4) | 2.0 (0.6; 5.7) |
| Cardiovascular risk factor at MRI | |||||||||
| Mean ± SD Systolic BP | 142 ± 20 | 119 ± 17 | 143 ± 23 | 134 ± 21 | 127 ± 19 | 145.7 ± 20 | 143.5 ± 18 | 148.6 ± 23.1 | 142.9 ± 20.6 |
| Hypertension (%) | 1968(79.8%) | 215 (27.1%) | 503 (65.8%) | 1082(49.5%) | 940 (43.6%) | 111 (29%) | 391 (69%) | 1080 (76.2%) | 543 (80.8%) |
| Diabetes Mellitus (%) | 255 (10.4%) | 80 (10.1%) | 68 (8.9%) | 221 (10.1%) | 261 (12.2%) | 15 (3.9%) | 51 (9.0%) | 115 (8.1%) | 184 (11.6%) |
| Current smoker (%) | 308 (12.4%) | 145 (18.2%) | 92 (12.0%) | 226 (10.3%) | 252 (11.7%) | 71 (18.7%) | 167 (29.5%) | 79 (5.6%) | 181 (11.3%) |
| Prevalent CVD at MRI, % | 328 (13.3%) | 53 (6.8%) | 68 (8.9%) | 116 (5.3%) | 242 (11.1%) | 29 (7.6%) | 38 (6.7%) | 58 (4.1%) | 229 (14.4%) |
Definition of baseline characteristics was uniform across all studies: Hypertension was defined as systolic blood pressure (BP) ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or being on antihypertensive treatment; Diabetes mellitus was defined as a casual or 2 hour postprandial blood glucose ≥200mg/dL, a fasting blood glucose ≥126mg/dL, or use of insulin or oral hypoglycemic agents; CVD (cardiovascular disease) was defined as presence of congestive heart failure, coronary heart disease or intermittent claudication.
ARIC and CHS expressed WMH as a grade (0–9 scale); all other studies expressed WMH as a volume (expressed in mL);
By design: In ASPS and CHS, participants with prevalent TIA or stroke were not included.
SD: Standard deviation; IQR: Inter-quartile range